Complix to Present at Upcoming BioEquity Europe 2013: http://t.co/jzPUX0k7Bp
FlandersBio informs you about important regional and national life sciences news. Send us your news. If your news is of interest to the life sciences community, we will post it on our website.
FlandersBio informeert u over belangrijk nieuws op het vlak van de biowetenschappen. Bezorg ons jouw nieuwtjes. Als het interessant is voor de sector, zullen wij het op onze website plaatsen.
The 5th ITERA Life-Sciences Consortium Symposium took place in Maastricht, the Netherlands, and showcased the progress of stem cell research and promising therapeutic applications. Thanks to solid scientific data, researchers confirmed that umbilical cord blood stem cells are one of the prime sources to be used in current stem cell transplants, ongoing research and future regenerative medicine. read more
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on developing innovative ophthalmic medicines, announces today that Thomas Clay has been appointed as a non-executive director with immediate effect. read more
MabCure, Inc. (OTCBB: MBCI), a leading developer of antibody-based diagnostics and treatments for ovarian and prostate cancer, today announced that it has signed a license agreement with Biotech Investment Corp. (“Biotech”), a Nevada-based biotechnology investment company. The agreement is an exclusive worldwide license to certain MabCure hybridoma clones producing antibodies against prostate cancer. In addition to the license fee paid to MabCure, Biotech will issue to MabCure 15% of its outstanding shares on a fully diluted basis and will pay a royalty of 12.5% on revenues. read more